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Background
Mortality due to non-AIDS-defining cancers (NADCs)
among HIV-positive patients, in the era of highly active
antiretroviral therapies, has yet to be completely defined.
To estimate the excess risk of death for each NADC among
people with AIDS (PWA), in comparison with the general
population, we conducted a population-based study in Italy.
Materials and methods
Between 1999 and 2006, 10,391 Italian citizens (15 years
of age) had been diagnosed with AIDS in Italy. These
PWAs constituted the population included in our study.
Death certificates were retrieved through a record-link-
age with the mortality databases at the National Institute
of Statistics. This allowed the extraction of information
about PWA dates of death, up to December 31, 2006.
The underlying cause of death, for each deceased PWA,
was identified following the International Classification
of Diseases, 10
th revision (ICD-10), applied also for the
general population. The excess risks of death for each
NADC were therefore estimated through standardized
mortality ratios (SMRs) with 95% confidence intervals
(CIs), in comparison with the Italian general population.
Results
Among 3,209 deceased PWA, 7.4% had died of NADCs,
with an SMR of 6.6 (95% CI 5.8-7.5). Significantly ele-
vated excess risks of death were found for a broad range
of cancers, notably for Hodgkin lymphoma (SMR=174),
cancers of liver (SMR=11.1), brain (SMR=10.0), head
and neck (SMR=8.2), lung (SMR=5.9), and myeloma and
leukemias (SMR=5.9). SMRs were higher among inject-
i n gd r u gu s e r s( I D U s )( S M R = 1 5 . 5f o ra l lN A D C )t h a n
among other HIV-transmission categories (SMR=4.8),
above all for liver cancer (SMR=65.2 among IDUs;
SMR=2.8 among non-IDUs).
Conclusions
We found particularly elevated SMRs for NADCs
among PWA, with several excess risks of death that
were higher than those expected, based on NADC inci-
dence recorded in Italy [1]. This finding could be
explained by the joint effect of an increased incidence of
some malignancies, markedly those related to smoking
and viral infections, and of their poorer prognosis
among PWA versus the general population.
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